secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003936
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian promotes Tom Ciulla to CMO; details 2024 TED trial timelines and FcRn milestones
--------------------------------------------------------------------------------

- Dr. Thomas Ciulla promoted to CMO, succeeding Dr. Barrett Katz who becomes consultant; Dr. Katz receives severance and consulting fee.
- Topline results from THRIVE Phase 3 (active TED) expected mid-2024; THRIVE-2 (chronic TED) by year-end 2024.
- Subcutaneous VRDN-003 pivotal study expected to start mid-2024 pending regulatory alignment.
- FcRn portfolio: VRDN-006 IND by year-end 2024; VRDN-008 NHP data in 2H 2024.
- Inducement grant of 62,000 stock options to new employee outside equity plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/0001193125-24-003936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/d109329d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer